Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies

Hashemi, Mehrdad; Zandieh, Mohammad Arad; Talebi, Yasmin; Rahmanian, Parham; Shafiee, Sareh Sadat; Nejad, Melina Maghsodlou; Babaei, Roghayeh; Sadi, Farzaneh Hasani; Rajabi, Romina; Abkenar, Zahra Oryan; Rezaei, Shamin; Ren, Jun; Nabvavi, Noushin; Khorrami, Ramin; Rashidi, Mohsen; Hushmandi, Kiavash; Entezari, Maliheh; Taheriazam, Afshin

doi:10.1016/j.biopha.2023.114392

Cited by 35 publications

(19 citation statements)

References 229 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the single-dose results, both the PC3 and the PDPC 3D cancer models showed resistance against all the repeated dose treatments except for the 7 d of 2000 nM treatment in the case of PDPC cancer model (figures 5(e) and (h)). The drug resistance observed in the 3D prostate cancer models can be due to the extrinsic drug resistance mechanisms in the cancer cells in the cancer models and the long time, and frequent administration of Docetaxel [41]. Numerous cancer types are initially sensitive to chemotherapy, but over time, resistance can develop through mechanisms such as DNA mutations, and metabolic changes that can promote inhibition or degradation of drugs [42][43][44].…”

Section: In Vitro Chemosensitivity Analysis Of the Developed Cancer M...mentioning

confidence: 99%

Development and characterisation of suitably bioengineered microfibrillar matrix-based 3D prostate cancer model for in vitro drug testing

Thilakan,

Nandakumar,

Balakrishnan

et al. 2023

Biomed. Mater.

View full text Add to dashboard Cite

Bioengineered 3D models that can mimic patient-specific pathologies in vitro are valuable tools for developing and validating anticancer therapeutics. In this study, microfibrillar matrices with unique structural and functional properties were fabricated as 3D spherical and disc-shaped scaffolds with highly interconnected pores and the potential of the newly developed scaffolds for developing prostate cancer model has been investigated. The newly developed scaffolds showed improved cell retention upon seeding with cancer cells compared to conventional electrospun scaffolds. They facilitated rapid growth and deposition of cancer-specific extracellular matrix through-the-thickness of the scaffold. Compared to the prostate cancer cells grown in 2D culture, the newly developed prostate cancer model showed increased resistance to the chemodrug Docetaxel regardless of the drug concentration or the treatment frequency. A significant reduction in the cell number was observed within one week after the drug treatment in the 2D culture for both PC-3 and patient-derived cells. Interestingly, almost 20-30 per cent of the cancer cells in the newly developed 3D model survived the drug treatment, and the patient-derived cells were more resistant than the tested cell line PC-3. The results from this study indicate the potential of the newly developed prostate cancer model for in vitro drug testing.

show abstract

Section: In Vitro Chemosensitivity Analysis Of the Developed Cancer M...mentioning

confidence: 99%

Development and characterisation of suitably bioengineered microfibrillar matrix-based 3D prostate cancer model for in vitro drug testing

Thilakan,

Nandakumar,

Balakrishnan

et al. 2023

Biomed. Mater.

View full text Add to dashboard Cite

show abstract

“…29 (VI) Mitotic inhibitors include paclitaxel and docetaxel; these drugs prevent cell mitosis. 30 The literature has revealed, in the last decade, that pyrazolo [1,5-a]pyrimidine structure 1 has promising bioactivity in numerous pharmacological applications, such as anticancer, 31 antibacterial, 32 anti-COVID-19, 33 anti-HIV, 34 TNF-a inhibitor, 35 and anti-Alzheimer. 36 12.12 ± 0.40 mM.…”

Section: Introductionmentioning

confidence: 99%

In vitro biological studies and computational prediction-based analyses of pyrazolo[1,5-a]pyrimidine derivatives

Almehizia,

Aboulthana,

Naglah

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Finding novel approaches to prevent and treat prostate and other urogenital cancers effectively is highly desirable and the search for plant-derived chemicals with a strong anticancer potential is ongoing and hopefully will result in novel agents that will overcome the resistance to current chemotherapy drugs [ 21 ]. Plant-derived chemicals such as polyphenols found in tea and wine may target molecules such as sphingosine-1 phosphate [ 22 ], an important player in cancer progression and metastasis, resulting in effects against prostate cancer [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Ursolic Acid against Prostate and Urogenital Cancers: A Review of In Vitro and In Vivo Studies

Kornel

Nadile

Retsidou

et al. 2023

IJMS

View full text Add to dashboard Cite

Prostate cancer is the second most diagnosed form of cancer in men worldwide and accounted for roughly 1.3 million cases and 359,000 deaths globally in 2018, despite all the available treatment strategies including surgery, radiotherapy, and chemotherapy. Finding novel approaches to prevent and treat prostate and other urogenital cancers effectively is of major importance. Chemicals derived from plants, such as docetaxel and paclitaxel, have been used in cancer treatment, and in recent years, research interest has focused on finding other plant-derived chemicals that can be used in the fight against cancer. Ursolic acid, found in high concentrations in cranberries, is a pentacyclic triterpenoid compound demonstrated to have anti-inflammatory, antioxidant, and anticancer properties. In the present review, we summarize the research studies examining the effects of ursolic acid and its derivatives against prostate and other urogenital cancers. Collectively, the existing data indicate that ursolic acid inhibits human prostate, renal, bladder, and testicular cancer cell proliferation and induces apoptosis. A limited number of studies have shown significant reduction in tumor volume in animals xenografted with human prostate cancer cells and treated with ursolic acid. More animal studies and human clinical studies are required to examine the potential of ursolic acid to inhibit prostate and other urogenital cancers in vivo.

show abstract

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies

Cited by 35 publications

References 229 publications

Development and characterisation of suitably bioengineered microfibrillar matrix-based 3D prostate cancer model for in vitro drug testing

Development and characterisation of suitably bioengineered microfibrillar matrix-based 3D prostate cancer model for in vitro drug testing

In vitro biological studies and computational prediction-based analyses of pyrazolo[1,5-a]pyrimidine derivatives

Ursolic Acid against Prostate and Urogenital Cancers: A Review of In Vitro and In Vivo Studies

Contact Info

Product

Resources

About